[{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Carmustine","moa":"||RNA | DNA | Glutathione reductase","graph1":"Oncology","graph2":"Phase II","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Mayo Clinic","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Mayo Clinic"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VI-0521","moa":"SGLT1\/SGLT2","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"VI-0609","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivus \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vivus

Vivus
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check all FDF Dossiers for
this supplier

Contact Us
PharmaScopic.com

Vivus

VISIT THE VIRTUAL BOOTH, Contact Details

DIGITAL CONTENT

Interview #SpeakPharma, Vlog #PharmaReel, Data Compilation #PharmaFlow, 50 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

1 All APIs, 1 USDMF

DEVELOPMENTS

26 Drugs in Development

26 Drugs in Development

FINISHED DOSAGE FORMULATIONS

13 FDF Dossiers, 13 FDA Orange Book

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

02

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

03

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

04

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

05

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

06

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

07

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

08

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

09

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

10

Vivus

U.S.A

ChemOutsourcing

Not Confirmed

1
2
3